According to our new market research study on “Cell Therapy Instruments Market to 2027 – Global Analysis and Forecast – by Product, Cell Type, Process, End User,” the market is expected to reach US$ 32,477.15 million by 2027 from US$ 12,340.03 million in 2019. The market is estimated to grow with a CAGR of 13.2% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth.

Factors such as increasing developments in cell therapy manufacturing and rising number of approvals for cell-based therapies are expected to influence market growth. On the other hand, high cost of cell therapy production and cell therapy are expected to hinder the market growth.

Request for Sample Report @ https://www.theinsightpartners.com/sample/TIPRE00003481/

The growing adoption of cell therapies increases the production of cell therapy instruments, and the research and technological developments in medical equipment introduce various automated systems in the market. Automated manufacturing reduces the chances of contamination and increases efficacy and efficiency for human and animal-derived cells as these advantages incline toward automated manufacturing processing.

The rising number of cell therapies have shifted the production of cell therapy products from a small volume to a large volume across the world. The centralized manufacturing facility conducted in a closed and fully automated system attracts automated cell therapy instruments. Increasing time efficiency is likely to foster the use of automated cell therapy instruments. Also, the evolution of cell therapy, from an academic and clinical setting to mass production and commercialization, increases the demand for automated instruments.

Moreover, companies are entering into strategic and technological developments for automated cell therapy instruments. For instance, in July 2020, Thermo Fisher Scientific Inc. and Lyell Immunopharma entered into a partnership to develop and manufacture processes in order to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve T cells' fitness and support the development of an integrated current good manufacturing practice (cGMP) compliant platform (system and software) along with reagents, consumables, and instruments. Such developments in the automated platforms will focus on entirely automated cell therapy instruments, which, in turn is likely to bolster market growth in the future.

Thermo Fisher Scientific Inc.; MERCK KGaA; Lonza; Cytiva (GE Healthcare Life Sciences); Terumo Corporation; BD; Miltenyi Biotec; STEMCELL Technologies Inc.; Sartorius AG; and Danaher Corporation (Beckman Coulter Inc.) are among the leading companies operating in the cell therapy instruments market.

The report segments global cell therapy instruments market as follows:

 By Product

1)    Consumables

2)    Equipment

a)  Single-Use Equipment

b)  Cell Processing Equipment

c)  Other Equipment

3)    Systems and Software

By Cell Type

4)    Human Cells

a)  Differentiated Cells

b)  Stem Cells

5)    Animal Cells

By Process          

6)    Cell Processing

7)    Process Monitoring and Quality Control

8)    Cell Preservation, Distribution, and Handling

Thermo Fisher Scientific Inc., and MERCK KGaA–are Notable Market Players in Cell therapy Instruments Market

Cell therapy is a procedure where living and intact cells are injected, implanted, or grafted into the patient's body. For instance, a person who has cancer is injected with T cells during his/her course of immunotherapy. Delivery of cell therapy instruments ranges from injections to surgical implantation using special devices. Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer. Other applications include cardiac conditions (myocardial infarction and heart failure), diabetes mellitus, bones and joints, genetic disorders, and wounds of the skin and soft tissues.

The growth of the cell therapy instruments market is mainly attributed to factors such as increasing developments in cell therapy manufacturing and rising number of approvals for cell-based therapies. On the other hand, high cost of cell therapy production and cell therapy are expected to hinder market growth.

Market leaders operating in the market have undertaken various organic and inorganic growth strategies in the cell therapy instruments market. The cell therapy instruments market majorly consists of the players such as Thermo Fisher Scientific Inc.; MERCK KGaA; Lonza; Cytiva (GE Healthcare Life Sciences); Terumo Corporation; BD; Miltenyi Biotec; STEMCELL Technologies Inc.; Sartorius AG; Danaher Corporation (Beckman Coulter Inc.) among others..

Several in organic approaches, such as product launches, and expansion in the cell therapy

instruments market, have resulted in the positive growth of the market. Likewise, inorganic

strategies such as mergers & acquisitions, and collaboration have help the company to strengthen its revenue, which allows the company to hold a strong position in the market.

Below is the list of the growth strategies done by the players operating in the cell  therapy instruments market :

March 2019           Lonza launched GS piggyBac, a versatile cell line engineering technology system which enable insertion of large fragment of DNA into transcriptionally active cells to develop therapeutic cell lines.

April 2019  STEMCELL technology has received USD 45 million aid from the government of Canada to expand its state of art facility and scale up its instruments and reagent business in cell therapy market.

December-2019    Sartorius acquires a major portion of cell culture media specialist Biological Industries based in Israel. This will expand the cell therapy instruments business of Sartorius in Middle East region.

April 2018  BD launched new BD FACSymphony S6 cell sorter which offers a better cell population sorting to analyze cell phenotypes for multiomics and immunology research purposes.

September 2017   Terumo BCT signed partnership agreement with Mallinckrodt in order to develop and distribute white blood cell processing system called THERAKOS CELLEX Photopheresis System

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1–646–491–9876